000 01226 a2200349 4500
005 20250518093139.0
264 0 _c20210118
008 202101s 0 0 eng d
022 _a1525-5069
024 7 _a10.1016/j.yebeh.2020.107043
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aShlobin, Nathan A
245 0 0 _aDrivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review.
_h[electronic resource]
260 _bEpilepsy & behavior : E&B
_c05 2020
300 _a107043 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAdiponectin
_xblood
650 0 4 _aAnticonvulsants
_xadverse effects
650 0 4 _aComorbidity
650 0 4 _aDiabetes Mellitus, Type 2
_xblood
650 0 4 _aEpilepsy
_xblood
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMetabolism, Inborn Errors
_xblood
650 0 4 _aMitochondria
_xmetabolism
650 0 4 _aObesity
_xblood
650 0 4 _aWeight Gain
_xphysiology
700 1 _aSander, Josemir W
773 0 _tEpilepsy & behavior : E&B
_gvol. 106
_gp. 107043
856 4 0 _uhttps://doi.org/10.1016/j.yebeh.2020.107043
_zAvailable from publisher's website
999 _c30785429
_d30785429